Effects of oral hyposensitization with recombinant Der f2 on immediate airway constriction in a murine allergic model

European Respiratory Journal

Volumn 11, Issue 1, 1998, Pages 144-150

  Yasue, M ^a   Yokota, T ^a   Yuasa, M ^a   Kajiwara, Y ^a   Suko, M ^b   Okudaira, H ^b  

^a ASAHI BREWERIES LTD   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Mouse; Oral immunotherapy; Recombinant Der f2

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2B; RECOMBINANT DER F2; UNCLASSIFIED DRUG;

AIRWAY CONSTRICTION; ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; HOUSE DUST ALLERGY; IMMUNOTHERAPY; INTRANASAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; BRONCHIAL SPASM; GLYCOPROTEINS; HYPERSENSITIVITY; IMMUNIZATION; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED STRAINS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031890990     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.11010144     Document Type: Article

References (54)

1. Miyamoto T, Oshima S, Ishizaki T, Sato S. Allergic identity between the common floor mite (Dermatophagoides farinae) and house dust as a causative antigen in bronchial asthma. J Allergy 1968; 42: 14-28.
2. Yasueda H, Mita H, Yui Y, Shida T. Isolation and characterization of a major allergen from the house dust mite Dermatophagoides farinae. Int Arch Allergy Appl Immunol 1986; 81: 214-223.
3. Haida M, Okudaira H, Ogita T, et al. Allergens of the house dust mite Dermatophagoides farinae - immunochemical studies of four allergic fractions. J Allergy Clin Immunol 1985; 75: 686-692.
4. Heymann PW, Chapman MD, Aalberse RC, Fox JW, Platts-Mills AE. Antigenic and structural analysis of group II allergens (Der f2 and Der p II) from house dust mites (Dermatophagoides spp). J Allergy Clin Immunol 1989; 83: 1055-1067.
5. Yuuki T, Okumura Y, Ando T, et al. Cloning and expression of cDNA coding for the major house dust mite allergen Der f2 in Escherichia coli. Agric Biol Chem 1991; 55: 1233-1238.
6. Iwamoto N, Nishiyama C, Yasuhara T, et al. Direct expression of Der f2, one of the major house dust mite allergens, in Escherichia coli. Int Arch Allergy Appl Immunol 1996; 109: 356-361.
7. Akagawa M, Mori T, Ando T, Okodaira T. Specific measurement of a major mite allergen, Der fII, by an enzyme-linked immunosorbernt assay system using monoclonal anti-Der fII antibodies. Biosci Biotech Biochem 1992; 56: 1725-1727.
8. Konzett H, Rössler R. Versuchsanordnung zu untersuchungen an der bronchialmuskulatur. Arch Exp Pathol Pharmakol 1940; 19S: 71-74.
9. Gieske TH, Baugh LE. Acute hypersensitivity to aerosolized histamine induced by aerosolized ovalbumin in guinea-pigs. Agents Actions 1992; 37: 198-200.
10. Iwama T, Shikada K, Yamamoto A, Sakashita M, Hibi M, Tanaka S. Inhibitory effect of NZ-107 on anaphylactic bronchoconstriction in guinea pigs and rats. Int Arch Allergy Immunol 1992; 97: 99-104.
11. Fujimura M, Tsujiura M, Songür N, Myou S, Matsuda T. Involvement of PAF in postallergic propranolol-induced bronchoconstriction in guinea-pigs. Eur Respir J 1996; 9: 2064-2069.
12. Misawa M, Takenouchi K, Abiru T, Yoshino Y, Yanaura S. Strain difference in an allergic asthma model in rats. Jpn J Pharmacol 1987; 45: 63-68
13. Watanabe N, Ovary Z. Antigen and antibody detection by in vivo methods. A reevaluation of passive cutaneous anaphylactic reactions. J Immunol Methods 1977; 14: 381-390.
14. Scordamaglia A, Pizzorno G, Caria M, et al. Immunologic and clinical evaluation of a 12-month course of specific immunotherapy. Ann Allergy 1989; 63: 31-36.
15. Djurup R. The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen-specific immunotherapy. Allergy 1985; 40: 469-486.
16. McHugh SM, Lavelle B, Kemeny DM, Patel S, Ewan PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990; 86: 521-532.
17. Warner JO, Soothill JF, Price JF, Hey EN. Controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with asthma. Lancet II 1978; 912-915.
18. Wahn U, Schweter C, Lind P, Lowenstein H. Prospective study on two different Dermatophagpides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immunol 1988; 82: 360-370.
19. Hejjaoui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagpides pteronyssinus extract. J Allergy Clin Immunol 1990; 85: 473-479.
20. Berrens L. Inhalant allergens in human atopic disease: their chemistry and modes of action. Ann NY Acad Sci 1974; 221: 183-199.
21. Castro FFM, Schumitz-Schmann M, Tother U, Kirschfink M. Complement activation by house dust: reduced reactivity of serum complement in patients with bronchial asthma. Int Arch Allergy Appl Immunol 1991; 96: 305-310.
22. Valenta R, Kraft D. Recombinant allergens for diagonosis and therapy of allergic diseases. Curr Opinion Immunol 1995; 7: 751-756.
23. Sehon LZ, Mohapatra SS. Induction of IgE antibodies in mice with recombinant grass-pollen antigens. Immunology 1992; 76: 158-163.
24. Vrtala S, Mayer P, Ferreira F, et al. Induction of IgE antibodies in mice and rhesus monkeys with recombinant birch pollen allergens: different allergenicity of Bet v 1 and Bet v 2. J Allergy Clin Immunol 1996; 98: 913-921.
25. Norman PS, Nicodemus CF, Creticos PS, et al. Clinical and immunologic effects of component peptides in allervax® cat. Int Arch Allergy Immunol 1997; 113: 224-226.
26. Valenta R, Vrtala S, Ebner C, Kraft D, Scheiner O. Diagnosis of grass pollen allergy with recombinant timothy grass (Phleum pratense) pollen allergens. Int Arch Allergy Immunol 1992; 97: 287-294.
27. Scheiner O, Aberer W, Ebner C, et al. Cross-reacting allergens in tree pollen and pollen related food allergy: implications for diagnosis of specific IgE. Int Arch Allergy Immunol 1997; 113: 105-108.
28. Chapman MD, Platts-Mills TAE. Purification and characterization of the major allergen from Dermatophagoides pteronyssinus P1. J Immunol 1980; 125: 587-592.
29. Chua KY, Greene WK, Kehal P, Thomas WR. IgE binding studies with large peptides expressed from Der p 2 cDNA constricts. Clin Exp Allergy 1991; 21: 161-166.
30. Shoji H, Hanawa M, Shibuya I, et al. Production of recombinant mite allergen Der fI in insect cells and characterization of products-removal of pro-sequence is essential to IgE-binding activity. Biosci Biotechnol Biochem 1996; 60: 621-625.
31. Thomas WR, Smith W, Hales BJ, Carter MD. Functional effects of polymorphisms of house dust mite allergens. Int Arch Allergy Immunol 1997; 113: 96-98.
32. Tari MG, Mancino M, Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol et Immunopathol 1990; 18: 277-284.
33. Ishii A, Ino Y, Haida M, Dohi M, et al. Inhibition of allergen-induced bronchoconstriction in sensitized guinea pigs by orally administered allergen. Int Arch Appl Immunol 1991; 94: 288-290.
34. Suko M, Mori A, Ito K, Okudaira H. Oral immunotherapy may induce T cell energy. Int Arch Allergy Immunol 1995; 107: 278-281.
35. Khoury SJ, Lider O, Al-Sabbagh A, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. Cellular Immunol 1990; 131: 302-310.
36. Weiner HL, Mackin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321-1324.
37. Miyamoto T, Akiyama K' Ohta K, Hayakawa T, Horiuchi Y. Effects of oral feeding of mite antigen upon production of homo-cytotropic antibodies. Ann Allergy 1980; 45: 108-114.
38. Zhang ZJ, Davidson L, Einsenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of poricine insulin. Proc Natl Acad Sci USA 1991; 88: 10252-10256.
39. Whitacre CC, Gienapp IE, Meyer A, Cox KL, Javed N. Treatment of autoimmune disease by oral tolerance to autoantigens. Clin Immunol Immunopathol 1996; 80: S31-S39.
40. Mowat AM, Steel M, Worthey EA, Kewin PJ, Garside P. Inactivation of Th1 and Th2 cells by feeding ovalbumin. Ann N Y Acad Sci 1996; 778: 122-132.
41. Takahashi I, Nakagawa I, Kiyono H, McGhee JR, Clements JD, Hamada S. Mucosal T-cells induce systemic energy for oral tolerance. Biochem Biophys Res Commun 1995; 206: 414-420.
42. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T-cells in oral tolerance. Nature 1995; 376: 177-180.
43. Garside P, Steel M, Liew FY, Mowat AM. CD4+ but not CD8+ T-cells are required for the induction of oral tolerance. Int Immunol 1995; 7: 501-504.
44. Mengel J, Cardillo F, Aroeira LS, Williams O, Russo M, Vaz NM. Anti-gamma delta T-cell antibody blocks the induction and maintenance of oral tolerance to ovalbumin in mice. Immunol Lett 1995; 48: 97-102.
45. Mosmann TR, Coffman RL. TH1 andTH2 cells. Different pattern of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-173.
46. de las Marinas, Sanz ML, DiÈguez I, Oehling A. IgE synthesis-enhancing factor: modification of its production in the course of long-term immunotherapy. J Invest Allergol Clin Immunol 1993; 3: 40-44.
47. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995; 25: 828-838.
48. O'Brien RM, Byron KA, Varigos GA, Thomas WR. House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-gamma and IL-4 expression by circulating T lymphocytes. Clin Exp Allergy 1997; 27: 46-51.
49. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154: 4187-4194.
50. Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dogdander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991; 87: 955-964.
51. Uekawa M, Ohashi Y, Esaki Y, et al. Whole blood histamine release rate during immunotherapy for nasal allergy. Acta Otolaryngol Suppl 1991; 486: 202-208.
52. Fanales-Belasio E, Ciofalo A, Zambetti G, et al. Intranasal immunotherapy with Dermatophagoides extract: in vivo and in vitro results of a double-blind placebo-controlled trial. Rhinology 1995; 33: 126-131.
53. Rak S. Effects of immunotherapy on the inflammation in pollen asthma. Allergy 1993; 48: 125-128.
54. Chen WY, Yu J, Wang JY. The effect of immunotherapy on bronchial hyperresponsiveness in asthmatic children. Asian Pac J Allergy Immunol 1994; 12: 15-20.